US/UK/Canada

Share

Pick a time period -
Tags ( Active)

First shipment of Immulina delivered to SCN’s new Immulina partner Aerus

In accordance to plan SCN has now received and delivered the first order from Aerus, SCN’s new Immulina partner, on totally USD 480 000 with cash payment. Aerus has also committed to purchase Immulina at a value of MSEK 250 during the coming five years in order to maintain the world-wide distribution rights. SCN also expects others order of the same size during this year.As a consequence of this agreement and other actions that have been taken and implemented during the last six months, the SCN management believes that positive cash flow will be shown during the third and fourth quarter.

Interim Report Q2 2009 from SCN

Scandinavian Clinical Nutrition, listed on NGM Equity and Oslo Axess, today releases the Q2 interim report for 2009. The entire report can be found in the attached pdf file, and on the company's website www.scnutrition.com.April-June 2009 in brief for the SCN group • Net sales for the period amounted to MSEK 7.0 • EBIT amounted to MSEK -11.3 • Loss for the period amounted to MSEK -4.8 • Earnings per share, basic and diluted, amounted to SEK -0.31 • New distribution contracts signed for thin400, Immulina and Coldizin, adding new markets in Europe • New Board Member elected: the Norwegian

Regarding Trade in SCN Shares on NGM Equity

As previously communicated, Scandinavian Clinical Nutrition AB (SCN) has applied for and been granted de-listing from Oslo Axess in Norway. From September 18 onwards, the SCN share will therefore only be traded on NGM Equity in Sweden, which may bring about certain changes for shareholders whose shares are registered in VPS in Norway.On August 18, 2009, SCN and Oslo Börs communicated that Oslo Börs had decided to approve SCN’s application regarding de-listing from Oslo Axess. The last day of trade on Oslo Axess will be September 17, 2009. From September 18 2009 onwards, trade in the SCN

SCN Signs Major World-Wide Distribution Agreement for Patented Immune Product

Scandinavian Clinical Nutrition AB (SCN) through its subsidiary has entered into a wide-ranging marketing and distribution agreement with US-based Aerus, formerly Electrolux North America. The agreement gives the direct sales company of Aerus Holdings, Naturals for Life, the world-wide exclusive rights to sell SCN’s patented immune product Immulina as a food supplement, with exception for markets where SCN already has partners in place.Under the agreement, the Aerus group commits to buying a minimum amount of Immulina well in excess of USD 30 million from SCN’s subsidiary Nordic Immotech

SCN Leaves Oslo Axess

As previously communicated, SCN has applied for de-listing of the company’s shares from the Norwegian Oslo Axess list. On August 17, 2009, Oslo Börs decided to approve the application. The last trading day for the SCN share on Oslo Axess will be September 17, 2009. The listing on NGM Equity remains unchanged.As previously communicated, an extraordinary general meeting in Scandinavian Clinical Nutrition AB (SCN) held on May 20, 2009, decided to apply for de-listing of the company’s shares from Oslo Axess. Oslo Börs has now decided to approve the application and de-list the company’s shares.

Publication of Prospectus from SCN

Today, August 12, 2009, Scandinavian Clinical Nutrition i Sverige AB (publ) publishes a prospectus regarding admission to trading of shares on NGM Equity due to the previously communicated directed share issue and issue of 3,700,000 shares.As previously communicated, at June 30, 2009, the Board of SCN decided to increase the company’s share capital through a directed share issue by virtue of authorization from the 2009 Annual General Meeting. The subscription price was set to SEK 1.00. In the previous release, the share capital increase was erroneously reported as SEK 320,000. The correct

Directed Share Issue in SCN to Settle Claim from Loan

A consortium of investors have offered Scandinavian Clinical Nutrition AB (SCN) an interest free loan, payable with shares in SCN. The Board of SCN has accepted the offer, and therefore decided to issue a maximum of 3,200,000 shares in SCN at a price of SEK 1 per share to the consortium, by virtue of authorization from the 2009 Annual General Meeting.In accordance with SCN’s previously communicated strategy aiming to strengthen the company’s solidity and financial situation, the Board of SCN has accepted an offer from a consortium of investors regarding an interest free loan. By virtue of

Norwegian Investor Elected New Member of the Board by the SCN Annual General Meeting

At the Annual General Meeting in Scandinavian Clinical Nutrition i Sverige AB (publ) today, the Norwegian investor Tore Eiklid was elected new Member of the Board.“I am very glad to announce that Tore Eiklid has been elected new Member of the Board of SCN. He has extensive experience of the international financial market and a vast network, especially in Norway, and will be a very good complement to the other Board Members. I look forward to continuing as Chairman of the Board for another year, and to seeing the results of our new strategy and all the measures taken to strengthen the

SCN Plans to Sell Additional Shares in Scandivir

As communicated to the market in previous press releases, for example on March 30, 2009, Scandinavian Clinical Nutrition AB (SCN) has sold parts of the company’s shareholding in Scandivir AB in order to strengthen the company’s financial situation. With reference to the article in the Norwegian financial magazine Finansavisen today, SCN hereby clarifies that the company plans to sell additional parts or all of the company’s shares in Scandivir, in line with the previously communicated strategy. In the previous transactions, Scandivir has been valued to +/- MSEK 100. SCN has good reason to

Notice of Annual General Meeting

To the shareholders of Scandinavian Clinical Nutrition i Sverige AB (publ) Please be informed that the Annual General Meeting (AGM) of Scandinavian Clinical Nutrition i Sverige AB (publ) (”the Company” or “SCN”) will be held on Friday, June 26, 2009 at 10.00 at Kungsgatan 37, Stockholm, SwedenAttendance at the AGM Shareholders wishing to attend the AGM need to be listed as shareholders in a printed or otherwise presented version of the complete Share Register depicting the conditions on Thursday, June 18, 2009, and to register the intention to attend the meeting with the Company by mail,

Press Release from Extraordinary General Meeting in Scandinavian Clinical Nutrition i Sverige AB (publ)

Today, May 20, 2009, an Extraordinary General Meeting in Scandinavian Clinical Nutrition AB (SCN) decided to apply for de-listing of the Company’s shares from the Norwegian Oslo Axess list. The listing on the Swedish NGM Equity list however remains unchanged.The Board’s motives for the proposal were in short the following: • the trade in the Company’s shares on Oslo Axess has been very limited • the spread of the shares in Norway is very limited • a double stock exchange listing requires significant resources, both in terms of costs and workload • the Company has its domicile and

SCN Interim Report January - March 2009

Net sales for the period amounted to MSEK 11.5 (16.3)EBIT amounted to MSEK -6.5 (-4.9)Loss for the period amounted to MSEK 9.0 (-6.6)Earnings per share, basic and diluted, amounted to SEK 0.48 (-0.45)Action plan to lower the costs and strenghten the balance sheet has been successfully initiated“After a couple of years of negative results and cash flows, I’m very pleased to see that the steps taken at beginning of 2009 to lower the company’s cost base and reducing the debt ratio already have started to give effect. The group’s operating costs have decreased by 15% compared to Q1 last

More than 89 percent of the convertible bond holders transferred their bonds to SCN in return for shares in Scandivir. 22 MSEK of interest bearing debt eliminated.

Scandinavian Clinical Nutrition (SCN) has now reduced the long-term debt deriving from the convertible bond issue in May 2008 with more than 22 MSEK. More than 89.4 percent of the bond holders have now received shares in Scandivir AB in return at a valuation of 100 MSEK. With this transaction completed, SCN is on the right track of becoming debt-free. SCN is continuing to re-assess non-core assets in order to reduce the debt burden.The Extraordinary General Meeting (EGM) in SCN on March 31, 2009 decided to offer the holders of the convertible bonds (“Bonds”) which were issued in May 2008 to

SCN Agrees to Buy-out of Non-core Distribution Agreement for MSEK 2

Scandinavian Clinical Nutrition (SCN) will receive SEK 2 million in cash by the end of May 2009 from its client Hirapharm S.A.R.L. to mutually terminate the distribution of third party products in France, Belgium and Luxembourg.The buy-out by Hirapharm relates to an exclusive distribution agreement for third party products (Femal and Poltit) from the Swedish company Natumin Pharma AB. Prior to the buy-out, SCN and Natumin had been working jointly on marketing and distributing some of Natumin’s products in the French-speaking region of Europe and this deal now leaves the door open for

SCN Signs Strategic, Regional Agreement for Coldizin and Immulina in South Eastern Europe

Scandinavian Clinical Nutrition AB (SCN) has entered into an exclusive, strategic distribution and supply agreement for the patented products Coldizin and Immulina in South Eastern Europe with a leading company in the Greek health market, Alapis S.A.Under the agreement, Alapis S.A. will exclusively market and distribute Coldizin and Immulina each in eight countries: Greece, Serbia, Bulgaria, Romania, Croatia, Slovenia, Montenegro, Bosnia-Herzegovina, FYRM and Albania. The initial focus will be the launch of both SCN products in Greece and Serbia during Q3 2009, with the other markets to

Annual Report SCN 2008

Scandinavian Clinical Nutrition i Sverige AB (publ) releases the Annual Report for 2008.From today onwards, the 2008 Annual Report of Scandinavian Clinical Nutrition AB is available on the company’s website www.scnutrition.com. A paper version can be ordered via mail (SCN AB, Stora Nygatan 7, Stockholm), via phone +46 8 586 107 80, via fax +46 8 222 006, or via e-mail info@scnutrition.com.The Annual General Meeting takes place in Stockholm on June 26, 2009.In comparison with the information presented in the unaudited Year-End and Q4 Report, one event has taken place that requires

Notice of Extraordinary General Meeting in SCN

The Board of Scandinavian Clinical Nutrition AB (SCN) today decided to propose an Extraordinary General Meeting to apply for de-listing of the company’s shares from Oslo Axess.The Board proposes that the EGM decides to apply to Oslo Börs for de-listing of the Company’s shares from Oslo Axess. No change is however proposed regarding the listing on NGM Equity. The Board’s motives for the proposal are in short the following:• the trade in the Company’s shares on Oslo Axess has been very limited• the spread of the shares in Norway is very limited• a double stock exchange listing requires

Clarification: Share Issue in SCN Registered in March

Through registration of the share issue which was carried out in January at the Swedish Companies Registration Office, the number of shares in Scandinavian Clinical Nutrition AB (SCN) increased with 1,780,000 shares from 16,023,284 to 17,803,284 shares during March, 2009.The company only has one class of shares, and the number of voting rights is therefore the same as the number of shares in the company.This information is published with reference to chapter 4, section 9 in the Swedish Financial Instruments TradingAct.

Product from SCN Has Effect on the H1N1 Virus

In previous press releases, Scandinavian Clinical Nutrition (SCN) has described positive results from a study where the patented product Immulina has been tested against the influenza virus H1N1, which now has been tied to the swine flu.The study results showed that taking Immulina caused a significant reduction of both clinical symptoms and lung tissue damage after infection by the influenza virus H1N1, the cause of the new swine flu epidemic, compared to placebo. The study was conducted during 2008 at Louisiana State University in USA, and animal studies have also been conducted at

SCN Extends UK Partnership with two more Products

Scandinavian Clinical Nutrition AB (SCN) has extended its collaboration with Vital Life International Ltd by adding two further unique products, thin400 and Immulina, to the product portfolio that will be launched and marketed in the UK, Ireland and the Channel Islands.“I am pleased that we are taking the next step in our business relationship with Vital Life already. In March we agreed on exclusive rights for the cold product Coldizin, and now Vital Life takes the further step on committing to launch the diet product thin400 and the immune system product Immulina. I have high hopes in

Term for Offer to Holders of Convertible Bonds in SCN Prolonged

The Board of Scandinavian Clinical Nutrition AB (SCN) today decided to prolong the term for the offer to holders of convertible bonds in SCN to buy shares in Scandivir until April 24, 2009.On May 12, 2008, an Extraordinary General Meeting (EGM) in SCN decided to issue convertible bonds. On March 31, 2009, an EGM decided to offer the holders of the bonds to transfer their bonds, and the rights attached, to SCN in return for shares in Scandivir AB.The term of the offer was set to April 17, and as per today, subscription forms for a total amount of close to MSEK 19 (out of the total amount

SCN Signs LOI for Sale of Immulina Rights

Scandinavian Clinical Nutrition AB (SCN) has entered into a Letter of Intent (LOI) with PhytoLab Solutions, Inc. part of the Lifequest group, outlining the intended sale of certain rights to the product Immulina. The LOI also extends the standstill agreement regarding PhytoLab Solutions’ option to acquire the SCN subsidiary containing the rights to Immulina, against a further upfront consideration of USD 1 million.“I am pleased we have reached this first step in the negotiation stage with Lifequest regarding the sale of rights to Immulina. The LOI gives both parties a framework to base our

There are no items matching the current filter
There are no more items matching the current filter
Back to top